Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 27-35

  Morgan, Christopher Ll ^a   Evans, Marc ^b   Toft, Anders D ^c   Jenkins Jones, Sara ^a   Poole, Chris D ^a   Currie, Craig J ^d  

^a Pharmatelligence ^*  (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c Novo Nordisk Ltd   (United Kingdom)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Biphasic human insulin; Biphasic insulin aspart; Effectiveness; Insulin analogues; Premixed insulin

Indexed keywords

BIPHASIC INSULIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNITED KINGDOM; WEIGHT CHANGE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BODY WEIGHT; CHILD; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952491611     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.023     Document Type: Article

References (20)

1. Currie C.J., Morgan C.L., Poole C.D., et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006, 22:1523-1534.
2. Wild D., von Maltzahn R., Brohan E., et al. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007, 68:10-15.
3. Testa M.A., Turner R.R., Hayes J.F., Simonson D.C. Patient satisfaction and quality of life in type 1 diabetes: A randomized trial of injectable vs inhaled insulin. Diabetes 2001, 50(Suppl 2):A45.
4. Garber A.J., Ligthelm R., Christiansen J.S., Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human?. Diabetes Obes Metab 2007, 9:630-639.
5. Warren M.L., Conway M.J., Klaff L.J., et al. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004, 66:23-29.
6. Halimi S., Raskin P., Liebl A., et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005, 27(Suppl B):S57-S74.
7. Gough S.C., Tibaldi J. Biphasic insulin aspart in type 2 diabetes mellitus: An evidence-based medicine review. Clin Drug Investig 2007, 27:299-324.
8. Boehm B.O., Vaz J.A., Brøndsted L., Home P.D. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004, 15:496-502.
9. McNally P.G., Dean J.D., Morris A.D., et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: A double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007, 30:1044-1048.
10. McSorley P.T., Bell P.M., Jacobsen L.V., et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002, 24:530-539.
11. Davidson J.A., Liebl A., Christiansen J.S., et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis. Clin Ther 2009, 31:1641-1651.
12. Boehm B.O., Home P.D., Behrend C., et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002, 19:393-399.
13. Raja-Khan N., Warehime S.S., Gabbay R.A. Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes. Vasc Health Risk Manag 2007, 3:919-935.
14. The Health Improvement Network (THIN) Database CSD/EPIC, Accessed August 26, 2010. http://www.epic-uk.org.htm.
15. Townsend P., Phillimore P., Beattie A. Health and Deprivation: Inequalities in the North 1988, Croon Helm, London.
16. Crager M.R. Analysis of covariance in parallel-group clinical trials with pretreatment baselines. Biometrics 1987, 43:895-901.
17. Hilbe J.M. Logistic Regression Models 2009, Chapman & Hall/CRC Press, Boca Raton, Fla.
18. Collett D. Modelling Survival Data in Medical Research 2003, Chapman & Hall/CRC Press, Boca Raton, Fla.
19. Mudaliar S.R., Lindberg F.A., Joyce M., et al. Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999, 22:1501-1506.
20. Heise T., Heinemann L., Hövelmann U., et al. Biphasic insulin aspart 30/70: Pharmacokinetics and pharmacodynamics in comparison with once-daily biphasic human insulin and Basal-bolus therapy. Diabetes Care 2009, 32:1431-1433.